Merck (MRK) Income towards Parent Company (2009 - 2026)
Merck (MRK) reported Income towards Parent Company of -$4.2 billion for Q1 2026, down 182.77% year-over-year from $5.1 billion in Q1 2025, and down 242.1% quarter-over-quarter from $3.0 billion in Q4 2025.
Merck (MRK) Income towards Parent Company (2009 - 2026) Analysis & Trends
Merck (MRK) has 17 years of Income towards Parent Company data on file, last reported at -$4.2 billion in Q1 2026.
- Income towards Parent Company for Q1 2026 came in at -$4.2 billion, down 182.77% year-over-year; the trailing twelve-month figure through Mar 2026 was $9.0 billion (down 48.61% YoY), and the FY2025 annual result was $18.3 billion, up 6.6% from the prior year.
- Income towards Parent Company slipped to -$4.2 billion in Q1 2026 per MRK's latest filing, from $3.0 billion in the prior quarter.
- Over five years, Income towards Parent Company peaked at $5.8 billion in Q3 2025 and troughed at -$5.9 billion in Q2 2023.
- A 4-year average of $2.4 billion and a median of $3.7 billion in 2024 frame the typical range for Income towards Parent Company.
- The sharpest annual moves came in 2024 and 2026: Income towards Parent Company soared 405.38% in 2024, then slumped 182.77% in 2026.
- A 4-year view of Income towards Parent Company shows it stood at -$1.2 billion in 2023, then soared by 405.38% to $3.7 billion in 2024, then decreased by 20.89% to $3.0 billion in 2025, then plunged by 242.1% to -$4.2 billion in 2026.
- Business Quant data shows MRK's Income towards Parent Company at -$4.2 billion in Q1 2026, $3.0 billion in Q4 2025, and $5.8 billion in Q3 2025.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Gsk | 93,699,046.73 Bn | 93,699,041.77 Bn | 7.76 Bn |
| 2 | Eli Lilly | 1,012.06 Bn | 1,006.77 Bn | 16.22 Bn |
| 3 | Johnson & Johnson | 560.67 Bn | 538.62 Bn | 15.96 Bn |
| 4 | AbbVie | 402.20 Bn | 392.85 Bn | 10.78 Bn |
| 5 | Merck | 298.59 Bn | 292.94 Bn | 12.09 Bn |
| 6 | Amgen | 188.77 Bn | 176.74 Bn | 5.87 Bn |
| 7 | Gilead Sciences | 160.22 Bn | 152.49 Bn | 5.52 Bn |
| 8 | Pfizer | 148.19 Bn | 135.42 Bn | -1.21 Bn |
| 9 | Bristol Myers Squibb | 116.72 Bn | 106.26 Bn | 8.07 Bn |
| 10 | Novartis Ag | 109.78 Bn | 109.09 Bn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -4.21 Bn |
| Dec 31, 2025 | 2.96 Bn |
| Sep 30, 2025 | 5.79 Bn |
| Jun 30, 2025 | 4.43 Bn |
| Mar 31, 2025 | 5.09 Bn |
| Dec 31, 2024 | 3.74 Bn |
| Sep 30, 2024 | 3.16 Bn |
| Jun 30, 2024 | 5.46 Bn |
| Mar 31, 2024 | 4.77 Bn |
| Dec 31, 2023 | -1.23 Bn |
| Sep 30, 2023 | 4.75 Bn |
| Jun 30, 2023 | -5.94 Bn |
| Mar 31, 2023 | 2.83 Bn |
| Dec 31, 2021 | -62.00 Mn |
| Jun 30, 2021 | 332.00 Mn |
| Mar 31, 2021 | 437.00 Mn |
| Dec 31, 2020 | 523.00 Mn |
| Sep 30, 2020 | 617.00 Mn |
| Jun 30, 2020 | 661.00 Mn |
| Mar 31, 2020 | 3.22 Bn |